| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
Flumorph’s primary mechanism of action is the inhibition of cellulose synthase, specifically the CesA3 enzyme, leading to disruption of cell wall synthesis and integrity. This causes hyphal swelling and lysis. Earlier studies suggested disruption of the F-actin cytoskeleton and polar deposition of newly synthesized cell wall materials.
|
|---|---|
| ln Vitro |
In vitro studies show that flumorph does not inhibit the synthesis of cell wall materials but disturbs the polar deposition of newly synthesized cell wall materials during cystospore germination and hyphal growth. Treated hyphae exhibit periodic swelling (“beaded” morphology) and disruption of tip growth.
|
| ln Vivo |
Flumorph effectively controls oomycete diseases in vivo, including those caused by Phytophthora melonis. It protects crops from downy mildew and other oomycete infections. The compound inhibits mycelial growth and spore germination, providing both protective and curative disease control.
|
| Enzyme Assay |
For non-cellular enzyme assays, flumorph’s inhibition of cellulose synthase (CesA3) can be evaluated using isolated enzyme preparations in cell-free systems. The enzyme activity is measured by monitoring the incorporation of radiolabeled UDP-glucose into cellulose. IC50 values are determined by incubating varying concentrations of flumorph with the enzyme and substrate, followed by quantification of synthesized cellulose.
|
| Cell Assay |
In vitro cellular assays for flumorph involve treating oomycete cultures (e.g., Phytophthora melonis) with the compound and assessing morphological changes. Hyphal growth inhibition is measured, and the development of “beaded” morphology is observed microscopically. Actin cytoskeleton organization can be visualized using FITC-phalloidin staining. Cell wall deposition is assessed using Calcofluor White staining.
|
| Animal Protocol |
In vivo animal experiments for flumorph are primarily conducted in plant models rather than animals. Plants infected with oomycete pathogens are treated with flumorph, and disease severity is assessed. Efficacy is measured by comparing lesion development, spore germination, and mycelial growth between treated and untreated plants. The compound’s protective and curative activities are evaluated in separate treatment protocols.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for flumorph are limited as it is primarily an agricultural fungicide rather than a therapeutic agent. The compound has a molecular weight of 371.40 and is expected to have moderate lipophilicity. Its formulation and application as a crop protectant influence its absorption, distribution, and persistence on plant surfaces and within plant tissues.
|
| Toxicity/Toxicokinetics |
Toxicological data for flumorph are primarily derived from agricultural safety assessments. As a carboxylic acid amide fungicide, it is expected to have low mammalian toxicity at recommended application rates. Standard ecotoxicological studies evaluate effects on non-target organisms including aquatic species, birds, and beneficial insects to establish safe use guidelines for agricultural applications.
|
| Additional Infomation |
Flumorph is a mixture composed of approximately equal amounts of (E)-Flumorph and (Z)-Flumorph. It is an agricultural fungicide used to control oomycete diseases such as downy mildew on vegetables and grapes. It is an antifungal agricultural chemical. It is a mixture of morpholine fungicides containing (Z)-Flumorph and (E)-Flumorph.
Flumorph was developed in China and is known by the code SYP-L190. It belongs to the carboxylic acid amide (CAA) fungicide class and is used to control oomycete diseases in various crops. The compound’s mechanism of action has been the subject of scientific investigation, with the current consensus identifying cellulose synthase (CesA3) as the primary target. |
| Molecular Formula |
C21H22FNO4
|
|---|---|
| Molecular Weight |
371.41
|
| Exact Mass |
371.153
|
| CAS # |
211867-47-9
|
| PubChem CID |
11057755
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.208g/cm3
|
| Boiling Point |
556.3ºC at 760mmHg
|
| Melting Point |
122-125 °C
|
| Flash Point |
290.3ºC
|
| Vapour Pressure |
0mmHg at 25°C
|
| Index of Refraction |
1.565
|
| LogP |
3.071
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
27
|
| Complexity |
512
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(N1CCOCC1)/C=C(C2=CC=C(OC)C(OC)=C2)\C3=CC=C(F)C=C3
|
| InChi Key |
BKBSMMUEEAWFRX-NBVRZTHBSA-N
|
| InChi Code |
InChI=1S/C21H22FNO4/c1-25-19-8-5-16(13-20(19)26-2)18(15-3-6-17(22)7-4-15)14-21(24)23-9-11-27-12-10-23/h3-8,13-14H,9-12H2,1-2H3/b18-14+
|
| Chemical Name |
(E)-3-(3,4-dimethoxyphenyl)-3-(4-fluorophenyl)-1-morpholin-4-ylprop-2-en-1-one
|
| Synonyms |
X5977; SYP-L190; Flumorph
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~269.25 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.73 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.73 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.73 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6924 mL | 13.4622 mL | 26.9244 mL | |
| 5 mM | 0.5385 mL | 2.6924 mL | 5.3849 mL | |
| 10 mM | 0.2692 mL | 1.3462 mL | 2.6924 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
